Kaleido, COPD Foundation Partner to Investigate KB109

Kaleido, COPD Foundation Partner to Investigate KB109

304109

Kaleido, COPD Foundation Partner to Investigate KB109

Kaleido Biosciences is teaming up with the COPD Foundation to investigate KB109, a small compound designed to modulate the gut microbiome — the community of microbes living in the intestines — as a potential treatment for chronic obstructive pulmonary disease (COPD). The decision was based on promising findings from a previous trial showing that people with mild-to-moderate COVID-19 and additional comorbidities (other medical conditions) taking KB109 recovered faster and had lower rates of medically attended…

You must be logged in to read/download the full post.